Infections

All Conditions

Symptoms and General Pathology

Respiratory Tract (Lung and Bronchial) Diseases

Nervous System Diseases

Communicable Diseases

Respiration Disorders

Respiratory Tract Diseases

Neurodegenerative Diseases

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Heparin

Calcium heparin

The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.

The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.

The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.

A large part is fasting samples.

Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300

Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).

Survey data can be linked to the blood samples.

Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000

The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.

Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)

Intervention on CVD (cardiovascular disease) and diabetes

VIP - Västerbotten Intervention Programme

Göran Hallmans, MD, PhD

Åsa Ågren, Databasehead

Lena Jakobsson, Coordinator

Göran Hallmans, MD PhD

NSHDS (Northern Sweden Health and Disease Study) is an umbrella term for a prospective biobank with related survey data. The sample collection consists of three subcohorts, Västerbotten Intervention Programme (VIP), Mammography Screening Project (MA) and MONICA (MONItoring of Trends and Determinants in CArdiovascular Disease). The blood samples are stored at the Northern Sweden Biobank.

The overall aim of the NSHDS is to support frontline research with particular emphasis on improving diagnostic tools for clinical use, as well as finding early markers of disease, using the blood samples, tissue and associated health data from the NSHDS. Furthermore, basic research regarding risk factors as well as pathogenetic pathways are promoted.

The prospective blood samples and related survey data can be linked to national registries for health outcomes such as cancer diagnosis for which there is a near 100% completeness of the data.

VIP - VÄSTERBOTTEN INTERVENTION PROGRAMME The VIP is a long-term project intended for health promotion of the population of the county of Västerbotten (approximately 254,000 inhabitants). All individuals 40, 50, and 60 years of age in the county are invited for screening. They are asked to complete a questionnaire concerning various lifestyle factors, including diet, and to donate a blood sample to be frozen for later research purposes. The cohort is population-based and the inclusion of individuals started 1985 and is ongoing. The participation rate has ranged between 48 and 67% of the population. But a large number has not been invited for screening. Among those invited the participation rate has been very high. The material is population based.

The blood samples consist primarily of EDTA (ethylenediaminetetraacetic acid) and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat. Questionnaire data are linked to blood samples.

The majority of samples are fasting samples. Number of individuals: 103,100 Individuals with repeated samples: 43,500 Sampling occasions: 151,200 (October 2016)

MA - MAMMOGRAPHY SCREENING PROJECT

Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).

Survey data can be linked to the blood samples.

Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000

THE MONICA STUDY

The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.

Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300

This registration will only cover blood sampling (screenings since 1990) and dietary data (optional MONICA study, screenings since 1986) as a part of the National Environmental Biobank. The participation rates have been 69-81%.

A separate registration is expected for the basic MONICA study.

The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.

Northern Sweden Health and Disease Study

Umeå University

Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

Diabetes Mellitus

Lung Diseases

Licia Iacoviello, MD, PhD

Cardiovascular disease and malignancies account for more than 70% of all causes of mortality and morbidity in Italy. There is a subtle balance between genetic determinants and lifestyle, that often defines the line between health and sickness. So far studies aiming at identifying risk factors have mainly come from Northern Europe and the USA. It was to understand this balance between genetics and environmental determinants better, and to tailor appropriate preventive strategies for Italian and other Southern European populations, that the Moli-sani study was launched, transforming a small Italian region into a large scientific laboratory: the "Molise lab".

Each participant received a thorough medical check-up at no cost to either him/her or the national health service, resulting in thousands of hours of free public health care. With a completely computerized system, Moli-sani is a "paperless" study, in which researchers and participants communicate using recently developed technologies such as mobile phone text messages (SMS). The biological data bank (the "MoliBank") is one of the largest in Europe. Paying particular attention towards innovation and new technologies, the Moli-sani study has placed itself at the cutting edge of a new paradigm crossing research and prevention

The cohort of the Moli-sani study has recruited 24,325 persons, aged \>35 years, resident in the Molise region.The latter covers an area of 4,438 Km2, including 136 towns. Participants are recruited from city-hall registries by a multistage sampling. Firstly townships were sampled in three major areas of Molise region, starting from the main cities (Campobasso, Termoli, Isernia) by cluster sampling, then, within each township, participants are selected by simple random sampling, using electronically generated numbers.Exclusion criteria are pregnancy at the time of recruitment, disturbances in understanding or willingness, current poly-traumas or coma, refusal to sign the Informed Consent form. All subjects identified are sent a letter inviting them to participate in the project, followed a few days later by a phone call. The recruitment started in the area of Campobasso, then it moved to the areas of Termoli.

Blood samples obtained from participants who had fasted overnight and had refrained from smoking for at least 6 h and stored in liquid nitrogen in the Biological bank of the Moli-sani study.

The Moli-sani Study

An Epidemiological Study of Risk Factors for Cardiovascular Disease and Tumors in an Adult Population of the Molise Region

sumbmission of a research proposal form to be approved by the Moli-sani scientific committee and signature of a research agreement.

Primary fatal and nonfatal incident cases of CHD (unstable angina, myocardial infarction, coronary revascularization and sudden death for unspecified cardiac event) and cerebrovascular disease that occurred in the cohort during follow-up

Primary fatal and nonfatal incident cases of cancer that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry

Primary fatal and nonfatal incident cases of heart failure that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry

Primary fatal and nonfatal incident cases of atrial fibrillation that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry

Primary incident cases of diabetes that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry or pharmacological prescription registry. Diabetes onset is defined as blood glucose ≥126 mg/dl or by use of specific pharmacological treatment

Neuromed IRCCS

MD, PhD

Behaviors and Mental Disorders

Rare Diseases

Respiratory Aspiration

Alzheimer Disease

Dementia

Brain Diseases

Central Nervous System Diseases

Tauopathies

Neurocognitive Disorders

Mental Disorders

Psychotic Disorders

Familial Alzheimer Disease

Mitogens

1. Chanting Om

   1. Sharp deep inhalation through nostrils
   2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.

   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.
2. Yogic Breathing:

   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.
   2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.
   3. Hold breath in this position for about 16 seconds.
   4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.
   5. Go to step a).

The participants will read a text of their choice for 20 minutes.

Yogic Breathing

The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.

Attention Control

Sundaravadivel Balasubramanian, PhD

Our aim is to analyze two ancient Tamil practices (chanting and breathing exercise) if they are capable of stimulating saliva containing agents that can be beneficial to the nervous system. Our study subjects will perform Tamil chanting and Tamil breathing exercise. Saliva will be collected before, during and after the exercises. We will quantify the specific proteins in these salivary samples. The results will benefit further studies in various patient populations.

Yogic Breathing Changes Salivary Components

Induction of Salivary Neuromodulators by Chanting and Breathing Exercise

Nerve growth factor will be quantified by ELISA and Western blotting.

Western blotting, Multiplex ELISA and Lipidomic analysis will be conducted in saliva samples to determine changes in molecular constituents before and after study exercise.

National Institutes of Health (NIH)

Medical University of South Carolina

Research Assistant Professor

Herve PICARD, MD MSc

In Paris, France, home hospice care for terminally ill patients is organized by four "palliative care networks". These networks are responsible for information sharing and coordination of all health care professionals working with the patient. Two different systems are in place to ensure continuity of care outside working hours, in such a setting. In the first system, palliative care specialists from the network are reachable over the phone 24/7 by the patient or its caregivers, whenever needed. In the second system, medical information about the patient, regularly updated by the network's medical team, is available to professionals via a secure website, so that in case the patient requires an urgent medical home visit outside working hours, the visiting physician has access to accurate information.

The study's goal is to compare patient's and caregiver's satisfaction between these two systems of continuity of care.

For that purpose, patients will be taken care of as usual by every palliative care network. In every instance where the patient or caregivers have reached out for medical help through the network's continuity of care system, the patient or caregiver will be called 5 days later by the investigation team to go through a satisfaction questionnaire (Likert scales)

Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks

Patient's (or caregiver's) satisfaction about the response given by the network's continuity of care system, after the patient or caregiver activated this system at night time or during week-ends or bank holliday, as measured on a 4-level Likert scale (verbal questionnaire by phone call)

Fondation Ophtalmologique Adolphe de Rothschild

Immune System Diseases

Neoplasms

Multiple Sclerosis

Sclerosis

Epilepsy

Neurodevelopmental Disorders

Brain Neoplasms

Autoimmune Diseases

Demyelinating Autoimmune Diseases, CNS

Autoimmune Diseases of the Nervous System

Demyelinating Diseases

Pediatric patients referred to the participating imaging centre for a standard MRI procedure.

Adult patients referred to the participating imaging centre for a standard MRI procedure, with neurological signs and symptoms.

Acquisition of MRI data with technique "Magnetic Resonance Fingerprinting"

MRI exam with Magnetic Resonance Fingerprinting

Magnetic Resonance Imaging (MRI) is an excellent method for diagnosis and staging of brain disease. However, lengthy scan times and sensitivity to patient motion limit its efficacy. To address this, a novel method has recently been demonstrated, called MR Fingerprinting (MRF). The investigators' improved implementation of MRF, featuring fully-quantitative data and a reduced sensitivity to patient motion, can be used to acquire an anatomical exam in less than five minutes at a standard resolution. The potential for wide applicability of this technique, combined with an implied reduction in complexity and cost of MRI exams, has generated wide interest. However, published studies have been limited to demonstrations in healthy volunteers, and the effectiveness of MRF in the clinical practice has not yet been proven. Here, the investigators aim to assess the efficacy of MRF in performing diagnostic exams avoiding sedation in children and for increasing diagnosis rates in challenging adult patients.

Due to its unrivalled diagnostic and prognostic capabilities, as well as the absence of harmful effects from ionizing radiation, MRI is often the radiological method of choice in children. However, radiology units have to face the inability to produce motion-free images especially in young children, even more so in those affected by neurological or neuropsychiatric disorders. These children are often incapable of completely following verbal instructions and cannot remain still in the scanner for a full exam. To avoid uncontrolled motion and the anxiety derived from long examinations, the majority of young children are sedated. However, sedation represents an extra procedure, carrying its own possible adverse effects, procedural complications as well as additional costs. Producing diagnostic, artefact-free images in a short time in children without sedation is thus an unmet need. The investigators' first hypothesis is that MR Fingerprinting can be used in a number of cases to perform a fast and diagnostic exam in children without using sedation.

The advantages of a fast, motion-resistant quantitative scan are not limited to paediatrics but could see wide application.

Disorders of movement such as tremor-dominant Parkinson's disease and severe cognitive impairments such as Alzheimer's disease represent a big challenge when referred to MRI. Although MRI is not a major player in diagnosing such diseases, these patients often require an exam in order to exclude other pathologies with similar clinical manifestations and to diagnose or follow-up other concomitant conditions. Patients with expansive intracranial lesions or requiring frequent follow-up, like those affected by inflammatory disease of the central nervous system, need to undergo long and demanding procedures, and they can eventually get into significant distress. The image quality of standard MRI with these challenging patient groups is often poor, as they cannot lay still or are unable to follow instructions. The investigators' second hypothesis is that MRF can be used to increase diagnosis rates of exams in difficult adult populations, reducing the time spent in the scanner and thus reducing wasted procedures and cost, and increasing patient comfort.

Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?

Aumentare il Potere Diagnostico Riducendo la Durata Dell'Esame: MR Fingerprinting Soddisfa le Aspettative?

To evaluate diagnosis rates with MRF in pediatric patients and challenging adult populations

Azienda Ospedaliero, Universitaria Pisana

IRCCS Fondazione Stella Maris

Researcher

Inflammation

Cognitive Dysfunction

Necrosis

Cognition Disorders

1.0 mg/kg XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.

1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 12 weeks.

XPro1595 will be delivered by subcutaneous injection once a week.

XPro1595

Placebo will be delivered by subcutaneous injection once a week

Placebo

Tara Lehner

The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with neuroinflammation (APOE4) and to evaluate safety, tolerability, and efficacy of XPro1595.

This study is designed as a Phase 2, double-blind randomized, placebo-controlled study investigating the safety, tolerability, and efficacy of XPro1595 in patients with MCI. The planned dose is 1.0 mg/kg of XPro1595 and matching placebo.

* (2:1) XPro1595 (1mg/kg), placebo
* Weekly subcutaneous injections

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation

Change in Goal Attainment Scale (GAS)

The achievement of each goal is rated on a 5-point attainment scale (-2, -1, 0, +1, +2) to allow standardized scoring of personalized outcomes. A participant's overall goal attainment is quantified using a formula that takes into account the number of goals that have been set, and the extent to which they are correlated with each other. For each identified goal area, the caregiver will be asked to give a detailed description of the patient's current (baseline) status and goal status, which will be recorded at the -1 and 0 levels on the 5-point scale, respectively. The remaining levels of the scale will then be set: somewhat better than the goal (+1), much better than the goal (+2), and much worse than the goal (-2).

To evaluate the effect of XPro1595 compared with placebo on goal attainment scores

Change from Screening to Week 12 in activity metrics (time spent lying, sitting, standing, stepping, upright, in walking bouts, in-context specific walking bouts; number of steps, and sit-to-stand transitions) as measured by the activity monitor. Physical activity will be measured in real time using the activity monitor worn on the patient's wrist. Total activity counts per minute (higher activity counts = more activity) and number of steps taken will be derived from data. Patients will be equipped with the monitoring device during the screening period and activity metrics will be measured for 7 days prior to each EMACC assessment. Data will be measured at Screening, Week 1, Week 3, Week 6, Week 9 and Week 12.

To assess the effect of XPro1595 compared to placebo on measures of activity

The Multidimensional Psychological Questionnaire (MPsQ) questionnaires have been designed to specifically measure patient personality characteristics associated with the placebo response. The MPsQ questionnaires are self-reported, and each item is rated on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree).

MPsQs will be completed by the patient and separate MPsQs will be completed by the study partner at screening.

MPsQs will be completed by the patient and separate MPsQs will be completed by the study partner prior to investigational product administration.

The patient and study partner will complete MPsQs at Screening and Week 1.

To measure patient personality characteristics associated with the placebo response.

Change from Baseline to Week 12 in the Early and Mild Alzheimer's Cognitive Composite (EMACC) (Jaeger 2017) made up of the following tests:

* International Shopping List Test- Immediate recall (Word List Learning Test-Immediate recall)
* Trail Making Test Part A and B
* Digit Symbol Coding Test
* Digit Span Forward and Backward
* Category Fluency Test (DKEFS)
* Letter Fluency Test (DKEFS)

To assess the efficacy of XPro1595 compared with placebo on cognitive performance in patients with MCI

Change from Screening to Week 12 in Cogstate Composite mean score.

Cogstate is a brief, computerized, neuropsychological battery to evaluate cognitive impairments in mild cognitive impairment (MCI), and Alzheimer's disease (AD). CogState assesses attention and memory functions - including Information processing speed, Visual attention, Working memory and Visual learning. Cogstate scores are measured on a linear scale (with no maximum score). A reduction in scores compared to baseline signifies an improvement in cognitive functions.

The Cogstate battery will be administered at Screening and each week for 12 weeks.

To assess the efficacy of XPro1595 compared with placebo on cognitive performance in patients with MCI

Change from Screening to Week 12 in myelin content.

Change from Screening to Week 12 in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid)

To assess the efficacy of XPro1595 compared with placebo on blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid)

Change from Screening to Week 12 in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)

To assess the efficacy of XPro1595 compared with placebo on blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)

Change from Screening to Week 12 in MRI neuroinflammation (White matter Free Water)

To assess the efficacy of XPro1595 compared with placebo on imaging neuroinflammation

Change from Screening to Week 12 in regional brain glucose uptake as measured by F-fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) scans

Alzheimer's Disease (AD) is characterized by a chronic brain glucose deficit. White matter glucose deterioration is also evident in Mild Cognitive Impairment (MCI) and specific to limbic fascicles. We will quantify the change in regional brain glucose uptake for gray matter and white matter tracts using PET imaging and the F-fluorodeoxyglucose (FDG) radiotracer. PET maps will be registered to Magnetic Resonance (MR) anatomical images and corrected for partial volume effect. Standard uptake value ratios (SUVr) will be calculated using the cerebellum as a reference region.

FDG-PET scans will be performed at Screening and Week 12.

To assess the efficacy of XPro1595 compared with placebo on imaging markers of brain quality

Change from Baseline to Week 12 in MRI Apparent Fiber Density (AFD)

To assess the efficacy of XPro1595 compared with placebo on axonal integrity in patients with MCI

Change from Screening to Week 12 in Neuropsychiatric Inventory (NPI-12) study partner items

To assess the effect of XPro1595 compared with placebo on non-cognitive behavioral symptoms in patients with MCI

Change from Screening to Week 12 in brain activity as measured by electroencephalogram (EEG) scans (Change in brain activity as measured by the EEG in microvolts).

Specifically, a series of EEG markers previously associated with AD (Horvath et al. 2018) including high and low frequency band powers, the P300, and Mismatch Negativity (MMN) event-related potentials will be evaluated.

An EEG scan will be administered at Screening and each week for 12 weeks.

To assess the efficacy of XPro1595 compared with placebo on brain activity in patients with MCI

Change from Baseline to Week 12 in language and speech patterns using Winterlight Labs analysis

To assess the effect of XPro1595 compared with placebo on speech and language in patients with MCI

Change from Screening to Week 12 in Alzheimer's Disease Cooperative Study - Mild Cognitive Impairment Activities of Daily Living (ADCS-MCI ADL)

The 23-item ADCS-MCI-ADL Scale has good test-retest reliability, will be utilized to assess performance functioning in MCI patients (Galasko et al., 1997; Douglas Galasko et al., 2006; Pedrosa et al., 2010). The ADCS-ADL includes 18 items from traditional basic ADL scales and 5 items from instrumental activities of daily living scales (IADL) The possible range of total scores for the ADL Scale is 0-53 and higher scores indicate better functioning. The internal reliability was .91( Galasko et al., 1997; Douglas Galasko et al., 2006; Pedrosa et al., 2010).

The ADCS-MCI ADL will be performed at Screening and Week 12.

To assess the effect of XPro1595 compared with placebo on Activities of Daily Living (ADL) in patients with MCI

Change from Screening to Week 12 in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

The CDR scale is a clinician-rated dementia staging system that tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5-point scale in which None = 0, Questionable = 0.5, Mild = 1, Moderate = 2, and Severe = 3. The global CDR score is established by clinical scoring rules and has values of 0 (no dementia), 0.5, (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.

To assess the effect of XPro1595 compared with placebo on cognition and global function in patients with MCI

Clinically significant abnormalities of laboratory values, physical findings, electrocardiogram findings and other safety assessments will be recorded as adverse events if the findings meet the defined criteria for adverse events.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Northern Sweden Health and Disease Study	NCT03426488	Cardiovascular ... Cancer Neurodegenerati... Respiratory Dis... Infection	VIP - Västerbot...	-	Umeå University
The Moli-sani Study	NCT03242109	Cardiovascular ... Cardiovascular ... Cancer Neurodegenerati... Diabetes Pulmonary Disea...		35 Years -	Neuromed IRCCS
Yogic Breathing Changes Salivary Components	NCT02108769	Alzheimer Disea... Neurodegenerati... Cancer	Yogic Breathing Attention Contr...	18 Years -	Medical University of South Carolina
Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks	NCT03336489	Neoplasms Neurodegenerati... Terminal Illnes...		18 Years -	Fondation Ophtalmologique Adolphe de Rothschild
Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?	NCT06251830	Neurodevelopmen... Neurodegenerati... Brain Tumor Multiple Sclero... Epilepsy	MRI exam with M...	4 Years -	IRCCS Fondazione Stella Maris
Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks	NCT03336489	Neoplasms Neurodegenerati... Terminal Illnes...		18 Years -	Fondation Ophtalmologique Adolphe de Rothschild
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation	NCT05321498	Mild Cognitive ... Alzheimer Disea... Dementia Brain Diseases Central Nervous... Nervous System ... Tauopathies Neurodegenerati... Mental Disorder...	XPro1595 Placebo	55 Years - 80 Years	Inmune Bio, Inc.
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation	NCT05321498	Mild Cognitive ... Alzheimer Disea... Dementia Brain Diseases Central Nervous... Nervous System ... Tauopathies Neurodegenerati... Mental Disorder...	XPro1595 Placebo	55 Years - 80 Years	Inmune Bio, Inc.

Spots Global Cancer Trial Database for neurodegenerative diseases